Protein abundance of clinically relevant multidrug transporters along the entire length of the human intestine

Molecular Pharmaceutics

Volumn 11, Issue 10, 2014, Pages 3547-3555

  Drozdzik, Marek ^a   Gröer, Christian ^b   Penski, Jette ^b   Lapczuk, Joanna ^a   Ostrowski, Marek ^a   Lai, Yurong ^c   Prasad, Bhagwat ^d   Unadkat, Jashvant D ^d   Siegmund, Werner ^b   Oswald, Stefan ^b  

^a POMERANIAN MEDICAL UNIVERSITY   (Poland)

^b UNIVERSITY MEDICINE GREIFSWALD   (Germany)

^c PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

^d UNIVERSITY OF WASHINGTON   (United States)

Author keywords

drug transporters; gene expression; human; intestine; protein abundance

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 2; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 3; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 1; ORGANIC CATION TRANSPORTER 3; PEPTIDE TRANSPORTER 1; CARRIER PROTEIN; COTRANSPORTER; MESSENGER RNA; MULTIDRUG RESISTANCE-ASSOCIATED PROTEIN 2; MULTIDRUG RESISTANCE-ASSOCIATED PROTEIN 3; ORGANIC CATION TRANSPORTER; SOLUTE CARRIER FAMILY 22 (ORGANIC CATION TRANSPORTER), MEMBER 3;

ADULT; ARTICLE; DUODENUM; HUMAN; HUMAN TISSUE; ILEUM; INTESTINE; INTESTINE ABSORPTION; JEJUNUM; MIDDLE AGED; ORGAN DONOR; PROTEIN CONTENT; PROTEIN EXPRESSION; SIGMOID; SMALL INTESTINE; YOUNG ADULT; COLON; FEMALE; GENETICS; IN VITRO STUDY; MALE; METABOLISM;

ADULT; COLON; DUODENUM; FEMALE; HUMANS; ILEUM; IN VITRO TECHNIQUES; INTESTINAL ABSORPTION; INTESTINE, SMALL; INTESTINES; JEJUNUM; MALE; MEMBRANE TRANSPORT PROTEINS; MIDDLE AGED; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; ORGANIC CATION TRANSPORT PROTEINS; RNA, MESSENGER; SYMPORTERS; YOUNG ADULT;

EID: 84907993610     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp500330y     Document Type: Article

References (56)

1. Estudante, M.; Morais, J. G.; Soveral, G.; Benet, L. Z. Intestinal drug transporters: An overview Adv. Drug Delivery Rev. 2013, 65 (10) 1340-1356
2. Fisher, M. B.; Labissiere, G. The role of the intestine in drug metabolism and pharmacokinetics: An industry perspective Curr. Drug Metab. 2007, 8 (7) 694-699
3. Konig, J.; Muller, F.; Fromm, M. F. Transporters and drug-drug interactions: Important determinants of drug disposition and effects Pharmacol. Rev. 2013, 65 (3) 944-966
4. Huang, S. M.; Strong, J. M.; Zhang, L.; Reynolds, K. S.; Nallani, S.; Temple, R.; Abraham, S.; Habet, S. A.; Baweja, R. K.; Burckart, G. J.; Chung, S.; Colangelo, P.; Frucht, D.; Green, M. D.; Hepp, P.; Karnaukhova, E.; Ko, H. S.; Lee, J. I.; Marroum, P. J.; Norden, J. M.; Qiu, W.; Rahman, A.; Sobel, S.; Stifano, T.; Thummel, K.; Wei, X. X.; Yasuda, S.; Zheng, J. H.; Zhao, H.; Lesko, L. J. New era in drug interaction evaluation: US Food and Drug Administration update on CYP enzymes, transporters, and the guidance process J. Clin. Pharmacol. 2008, 48 (6) 662-670
5. Schiller, C.; Frohlich, C. P.; Giessmann, T.; Siegmund, W.; Monnikes, H.; Hosten, N.; Weitschies, W. Intestinal fluid volumes and transit of dosage forms as assessed by magnetic resonance imaging Aliment. Pharmacol. Ther. 2005, 22 (10) 971-979
6. Berggren, S.; Gall, C.; Wollnitz, N.; Ekelund, M.; Karlbom, U.; Hoogstraate, J.; Schrenk, D.; Lennernas, H. Gene and protein expression of P-glycoprotein, MRP1, MRP2, and CYP3A4 in the small and large human intestine Mol. Pharmaceutics 2007, 4 (2) 252-257
7. Mouly, S.; Paine, M. F. P-glycoprotein increases from proximal to distal regions of human small intestine Pharm. Res. 2003, 20 (10) 1595-1599
8. Englund, G.; Rorsman, F.; Ronnblom, A.; Karlbom, U.; Lazorova, L.; Grasjo, J.; Kindmark, A.; Artursson, P. Regional levels of drug transporters along the human intestinal tract: Co-expression of ABC and SLC transporters and comparison with Caco-2 cells Eur. J. Pharm. Sci. 2006, 29 (3-4) 269-277
9. Hilgendorf, C.; Ahlin, G.; Seithel, A.; Artursson, P.; Ungell, A. L.; Karlsson, J. Expression of thirty-six drug transporter genes in human intestine, liver, kidney, and organotypic cell lines Drug Metab. Dispos. 2007, 35 (8) 1333-1340
10. Meier, Y.; Eloranta, J. J.; Darimont, J.; Ismair, M. G.; Hiller, C.; Fried, M.; Kullak-Ublick, G. A.; Vavricka, S. R. Regional distribution of solute carrier mRNA expression along the human intestinal tract Drug Metab. Dispos. 2007, 35 (4) 590-594
11. Seithel, A.; Karlsson, J.; Hilgendorf, C.; Bjorquist, A.; Ungell, A. L. Variability in mRNA expression of ABC- and SLC-transporters in human intestinal cells: Comparison between human segments and Caco-2 cells Eur. J. Pharm. Sci. 2006, 28 (4) 291-299
12. Zimmermann, C.; Gutmann, H.; Hruz, P.; Gutzwiller, J. P.; Beglinger, C.; Drewe, J. Mapping of multidrug resistance gene 1 and multidrug resistance-associated protein isoform 1 to 5 mRNA expression along the human intestinal tract Drug Metab. Dispos. 2005, 33 (2) 219-224
13. Barr, W. H.; Zola, E. M.; Candler, E. L.; Hwang, S. M.; Tendolkar, A. V.; Shamburek, R.; Parker, B.; Hilty, M. D. Differential absorption of amoxicillin from the human small and large intestine Clin. Pharmacol. Ther. 1994, 56 (3) 279-285
14. Fricker, G.; Drewe, J.; Huwyler, J.; Gutmann, H.; Beglinger, C. Relevance of P-glycoprotein for the enteral absorption of cyclosporin A: In vitro-in vivo correlation Br. J. Pharmacol. 1996, 118 (7) 1841-1847
15. Gramatte, T.; Oertel, R.; Terhaag, B.; Kirch, W. Direct demonstration of small intestinal secretion and site-dependent absorption of the β-blocker talinolol in humans Clin. Pharmacol. Ther. 1996, 59 (5) 541-549
16. Skottheim, I. B.; Jakobsen, G. S.; Stormark, K.; Christensen, H.; Hjelmesaeth, J.; Jenssen, T.; Asberg, A.; Sandbu, R. Significant increase in systemic exposure of atorvastatin after biliopancreatic diversion with duodenal switch Clin. Pharmacol. Ther. 2010, 87 (6) 699-705
17. Weitschies, W.; Bernsdorf, A.; Giessmann, T.; Zschiesche, M.; Modess, C.; Hartmann, V.; Mrazek, C.; Wegner, D.; Nagel, S.; Siegmund, W. The talinolol double-peak phenomenon is likely caused by presystemic processing after uptake from gut lumen Pharm. Res. 2005, 22 (5) 728-735
18. Tubic, M.; Wagner, D.; Spahn-Langguth, H.; Weiler, C.; Wanitschke, R.; Bocher, W. O.; Langguth, P. Effects of controlled-release on the pharmacokinetics and absorption characteristics of a compound undergoing intestinal efflux in humans Eur. J. Pharm. Sci. 2006, 29 (3-4) 231-239
19. Englund, G.; Jacobson, A.; Rorsman, F.; Artursson, P.; Kindmark, A.; Ronnblom, A. Efflux transporters in ulcerative colitis: Decreased expression of BCRP (ABCG2) and Pgp (ABCB1) Inflammatory Bowel Dis. 2007, 13 (3) 291-297
20. Wojtal, K. A.; Eloranta, J. J.; Hruz, P.; Gutmann, H.; Drewe, J.; Staumann, A.; Beglinger, C.; Fried, M.; Kullak-Ublick, G. A.; Vavricka, S. R. Changes in mRNA expression levels of solute carrier transporters in inflammatory bowel disease patients Drug Metab. Dispos. 2009, 37 (9) 1871-1877
21. Harwood, M. D.; Neuhoff, S.; Carlson, G. L.; Warhurst, G.; Rostami-Hodjegan, A. Absolute abundance and function of intestinal drug transporters: A prerequisite for fully mechanistic in vitro-in vivo extrapolation of oral drug absorption Biopharm. Drug Dispos. 2013, 34 (1) 2-28
22. Giacomini, K. M.; Huang, S. M.; Tweedie, D. J.; Benet, L. Z.; Brouwer, K. L.; Chu, X.; Dahlin, A.; Evers, R.; Fischer, V.; Hillgren, K. M.; Hoffmaster, K. A.; Ishikawa, T.; Keppler, D.; Kim, R. B.; Lee, C. A.; Niemi, M.; Polli, J. W.; Sugiyama, Y.; Swaan, P. W.; Ware, J. A.; Wright, S. H.; Yee, S. W.; Zamek-Gliszczynski, M. J.; Zhang, L. Membrane transporters in drug development Nat. Rev. Drug Discovery 2010, 9 (3) 215-236
23. Hillgren, K. M.; Keppler, D.; Zur, A. A.; Giacomini, K. M.; Stieger, B.; Cass, C. E.; Zhang, L. Emerging transporters of clinical importance: An update from the International Transporter Consortium Clin. Pharmacol. Ther. 2013, 94 (1) 52-63
24. Groer, C.; Bruck, S.; Lai, Y.; Paulick, A.; Busemann, A.; Heidecke, C. D.; Siegmund, W.; Oswald, S. LC-MS/MS-based quantification of clinically relevant intestinal uptake and efflux transporter proteins J. Pharm. Biomed. Anal. 2013, 85, 253-261
25. Engel, A.; Oswald, S.; Siegmund, W.; Keiser, M. Pharmaceutical excipients influence the function of human uptake transporting proteins Mol. Pharmaceutics 2012, 9 (9) 2577-2581
26. Tucker, T. G.; Milne, A. M.; Fournel-Gigleux, S.; Fenner, K. S.; Coughtrie, M. W. Absolute immunoquantification of the expression of ABC transporters P-glycoprotein, breast cancer resistance protein and multidrug resistance-associated protein 2 in human liver and duodenum Biochem. Pharmacol. 2012, 83 (2) 279-285
27. Schwarz, U. I.; Gramatte, T.; Krappweis, J.; Oertel, R.; Kirch, W. P-glycoprotein inhibitor erythromycin increases oral bioavailability of talinolol in humans Int. J. Clin. Pharmacol. Ther. 2000, 38 (4) 161-167
28. Edwards, A.; Ensom, M. H. Pharmacokinetic effects of bariatric surgery Ann. Pharmacother. 2012, 46 (1) 130-136
29. Oswald, S.; Haenisch, S.; Ludwig, K.; Bernhadt, J.; Modess, C.; Scheuch, E.; Cascorbi, I.; Siegmund, W. Influence of Roux-En-y Gastric Bypass Surgery on the Disposition of Paracetamol, Talinolol and Amoxicillin in Obese Patients Clin. Pharmacol. Ther. 2011, 89, S29
30. Dawson, P. A. Role of the intestinal bile acid transporters in bile acid and drug disposition Handb. Exp. Pharmacol. 2011, 201, 169-203
31. Oswald, S.; Haenisch, S.; Fricke, C.; Sudhop, T.; Remmler, C.; Giessmann, T.; Jedlitschky, G.; Adam, U.; Dazert, E.; Warzok, R.; Wacke, W.; Cascorbi, I.; Kroemer, H. K.; Weitschies, W.; von Bergmann, K.; Siegmund, W. Intestinal expression of P-glycoprotein (ABCB1), multidrug resistance associated protein 2 (ABCC2), and uridine diphosphate-glucuronosyltransferase 1A1 predicts the disposition and modulates the effects of the cholesterol absorption inhibitor ezetimibe in humans Clin. Pharmacol. Ther. 2006, 79 (3) 206-217
32. Tirona, R. G. Molecular mechanisms of drug transporter regulation Handb. Exp. Pharmacol. 2011, 201, 373-402
33. Giessmann, T.; Modess, C.; Hecker, U.; Zschiesche, M.; Dazert, P.; Kunert-Keil, C.; Warzok, R.; Engel, G.; Weitschies, W.; Cascorbi, I.; Kroemer, H. K.; Siegmund, W. CYP2D6 genotype and induction of intestinal drug transporters by rifampin predict presystemic clearance of carvedilol in healthy subjects Clin. Pharmacol. Ther. 2004, 75 (3) 213-222
34. Westphal, K.; Weinbrenner, A.; Zschiesche, M.; Franke, G.; Knoke, M.; Oertel, R.; Fritz, P.; von, R. O.; Warzok, R.; Hachenberg, T.; Kauffmann, H. M.; Schrenk, D.; Terhaag, B.; Kroemer, H. K.; Siegmund, W. Induction of P-glycoprotein by rifampin increases intestinal secretion of talinolol in human beings: A new type of drug/drug interaction Clin. Pharmacol. Ther. 2000, 68 (4) 345-355
35. Tirona, R. G.; Leake, B. F.; Merino, G.; Kim, R. B. Polymorphisms in OATP-C: Identification of multiple allelic variants associated with altered transport activity among European- and African-Americans J. Biol. Chem. 2001, 276 (38) 35669-35675
36. Chen, Y.; Teranishi, K.; Li, S.; Yee, S. W.; Hesselson, S.; Stryke, D.; Johns, S. J.; Ferrin, T. E.; Kwok, P.; Giacomini, K. M. Genetic variants in multidrug and toxic compound extrusion-1, hMATE1, alter transport function Pharmacogenomics J. 2009, 9 (2) 127-136
37. Kimchi-Sarfaty, C.; Oh, J. M.; Kim, I. W.; Sauna, Z. E.; Calcagno, A. M.; Ambudkar, S. V.; Gottesman, M. M. A "silent" polymorphism in the MDR1 gene changes substrate specificity Science 2007, 315 (5811) 525-528
38. Chen, L.; Hong, C.; Chen, E. C.; Yee, S. W.; Xu, L.; Almof, E. U.; Wen, C.; Fujii, K.; Johns, S. J.; Stryke, D.; Ferrin, T. E.; Simko, J.; Chen, X.; Costello, J. F.; Giacomini, K. M. Genetic and epigenetic regulation of the organic cation transporter 3, SLC22A3 Pharmacogenomics J. 2013, 13 (2) 110-120
39. Haenisch, S.; Laechelt, S.; Bruckmueller, H.; Werk, A.; Noack, A.; Bruhn, O.; Remmler, C.; Cascorbi, I. Down-regulation of ATP-binding cassette C2 protein expression in HepG2 cells after rifampicin treatment is mediated by microRNA-379 Mol. Pharmacol. 2011, 80 (2) 314-320
40. Brandsch, M. Drug transport via the intestinal peptide transporter PepT1 Curr. Opin. Pharmacol. 2013, 13 (6) 881-887
41. Cortvriendt, W. R.; Verschoor, J. S.; Hespe, W. Bioavailability study of a new amoxicillin tablet designed for several modes of oral administration Arzneimittelforschung 1987, 37 (8) 977-979
42. Weitschies, W.; Friedrich, C.; Wedemeyer, R. S.; Schmidtmann, M.; Kosch, O.; Kinzig, M.; Trahms, L.; Sorgel, F.; Siegmund, W.; Horkovics-Kovats, S.; Schwarz, F.; Raneburger, J.; Monnikes, H. Bioavailability of amoxicillin and clavulanic acid from extended release tablets depends on intragastric tablet deposition and gastric emptying Eur. J. Pharm. Biopharm. 2008, 70 (2) 641-648
43. Guo, X.; Meng, Q.; Liu, Q.; Wang, C.; Sun, H.; Kaku, T.; Liu, K. Construction, identification and application of HeLa cells stably transfected with human PEPT1 and PEPT2 Peptides 2012, 34 (2) 395-403
44. Evans, D. F.; Pye, G.; Bramley, R.; Clark, A. G.; Dyson, T. J.; Hardcastle, J. D. Measurement of gastrointestinal pH profiles in normal ambulant human subjects Gut 1988, 29 (8) 1035-1041
45. Jia, J.; Puls, D.; Oswald, S.; Jedlitschky, G.; Kuhn, J. P.; Weitschies, W.; Hosten, N.; Siegmund, W.; Keiser, M. Characterization of the intestinal and hepatic uptake/efflux transport of the magnetic resonance imaging contrast agent gadolinium-ethoxylbenzyl-diethylenetriamine-pentaacetic acid Invest. Radiol. 2014, 49 (2) 78-86
46. Keppler, D. The Roles of MRP2, MRP3, and OATP1B1 and OATP1B3 in Conjugated Hyperbilirubinemia Drug Metab. Dispos. 2014, 42, 561-565
47. de Waart, D. R.; van de Wetering, K.; Kunne, C.; Duijst, S.; Paulusma, C. C.; Oude Elferink, R. P. Oral availability of cefadroxil depends on ABCC3 and ABCC4 Drug Metab. Dispos. 2012, 40 (3) 515-521
48. Ming, X.; Knight, B. M.; Thakker, D. R. Vectorial transport of fexofenadine across Caco-2 cells: Involvement of apical uptake and basolateral efflux transporters Mol. Pharmaceutics 2011, 8 (5) 1677-1686
49. Naddaf, F.; Keiser, M.; Didrigkeit, K.; Oswald, S.; Scheuch, E.; Kock, K.; Kroemer, H. K.; Siegmund, W. In Vitro Effects of Intestinal and Hepatic Uptake Transporters on Talinolol Uptake Br. J. Clin. Pharmacol. 2010, 70, 23
50. Glaeser, H.; Bailey, D. G.; Dresser, G. K.; Gregor, J. C.; Schwarz, U. I.; McGrath, J. S.; Jolicoeur, E.; Lee, W.; Leake, B. F.; Tirona, R. G.; Kim, R. B. Intestinal drug transporter expression and the impact of grapefruit juice in humans Clin. Pharmacol. Ther. 2007, 81 (3) 362-370
51. Uchida, Y.; Ohtsuki, S.; Katsukura, Y.; Ikeda, C.; Suzuki, T.; Kamiie, J.; Terasaki, T. Quantitative targeted absolute proteomics of human blood-brain barrier transporters and receptors J. Neurochem. 2011, 117 (2) 333-345
52. Dresser, G. K.; Bailey, D. G.; Leake, B. F.; Schwarz, U. I.; Dawson, P. A.; Freeman, D. J.; Kim, R. B. Fruit juices inhibit organic anion transporting polypeptide-mediated drug uptake to decrease the oral availability of fexofenadine Clin. Pharmacol. Ther. 2002, 71 (1) 11-20
53. Rebello, S.; Zhao, S.; Hariry, S.; Dahlke, M.; Alexander, N.; Vapurcuyan, A.; Hanna, I.; Jarugula, V. Intestinal OATP1A2 inhibition as a potential mechanism for the effect of grapefruit juice on aliskiren pharmacokinetics in healthy subjects Eur. J. Clin. Pharmacol. 2012, 68 (5) 697-708
54. Schwarz, U. I.; Seemann, D.; Oertel, R.; Miehlke, S.; Kuhlisch, E.; Fromm, M. F.; Kim, R. B.; Bailey, D. G.; Kirch, W. Grapefruit juice ingestion significantly reduces talinolol bioavailability Clin. Pharmacol. Ther. 2005, 77 (4) 291-301
55. Tamai, I. Oral drug delivery utilizing intestinal OATP transporters Adv. Drug Delivery Rev. 2012, 64 (6) 508-514
56. Misaka, S.; Yatabe, J.; Muller, F.; Takano, K.; Kawabe, K.; Glaeser, H.; Yatabe, M. S.; Onoue, S.; Werba, J. P.; Watanabe, H.; Yamada, S.; Fromm, M. F.; Kimura, J. Green tea ingestion greatly reduces plasma concentrations of nadolol in healthy subjects Clin. Pharmacol. Ther. 2014, 95 (4) 432-438